ANI Pharmaceuticals (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 4,772 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Thomas Andrew Rowland sold 4,772 shares of the firm’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the completion of the sale, the senior vice president directly owned 38,730 shares in the company, valued at approximately $2,901,264.30. This trade represents a 10.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $70.49 on Friday. The company has a market cap of $1.58 billion, a price-to-earnings ratio of 20.98 and a beta of 0.52. The company has a 50-day moving average price of $79.12 and a 200-day moving average price of $85.35. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. ANI Pharmaceuticals, Inc. has a 12 month low of $56.71 and a 12 month high of $99.50.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Zacks/analyst bullishness — A Zacks piece highlights ANIP among four biotech names to watch for upside in 2026, citing new drug approvals and pipeline progress. Another Zacks story notes the consensus of Wall Street analysts implies roughly a 44.8% upside in ANIP, which could support buying interest if fundamentals continue to improve. 4 Biotech Stocks to Watch for Potential Upside in 2026 Analysts See a 44.84% Upside in ANI (ANIP)
• Neutral Sentiment: Analyst/market coverage piece — Yahoo published a “sizing up” note after a recent share-price pullback that reviews valuation and technicals; such coverage can attract traders looking to buy a dip but doesn’t itself guarantee direction. Sizing Up ANI Pharmaceuticals After Recent Share Price Pullback
• Neutral Sentiment: Short interest data appears non‑informative — a March note shows effectively zero reported short interest (and a 0.0 days-to-cover), suggesting short activity is not currently driving the move. This item is ambiguous given the odd/empty figures provided.
• Negative Sentiment: Insider selling — Several insiders disclosed open-market sales this week: VP Meredith Cook sold 500 shares (avg ~$72.62; SEC filing), insider Christopher Mutz sold 3,162 shares (avg ~$71.64; SEC filing), and SVP Thomas Rowland sold 4,772 shares (avg ~$74.91; SEC filing). Combined, these disclosures show executives trimming positions and likely contributed to downward pressure on the stock today. Meredith Cook Form 4 Christopher Mutz Form 4 Thomas Rowland Form 4

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ANIP. Arrowstreet Capital Limited Partnership purchased a new position in ANI Pharmaceuticals during the 3rd quarter valued at about $32,992,000. Balyasny Asset Management L.P. grew its holdings in ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after purchasing an additional 276,233 shares during the period. Divisadero Street Capital Management LP bought a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $21,454,000. Rubric Capital Management LP lifted its holdings in shares of ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after purchasing an additional 200,998 shares during the last quarter. Finally, UBS Group AG lifted its holdings in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the topic of several research analyst reports. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Barclays began coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price for the company. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.